Scarica l'app Stockscreener
0.027
0.86%
-0.0195
Dopo l'orario di chiusura:
.03
0.003
+11.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GRTX Giù?
Forum
Previsione
Galera Therapeutics Inc Borsa (GRTX) Ultime notizie
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics extends agreement deadline - Investing.com Australia
Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com
Galera Therapeutics holds annual stockholder meeting By Investing.com - Investing.com South Africa
Galera Therapeutics holds annual stockholder meeting - Investing.com India
Oral Mucositis Market to Expand Significantly by 2034, States DelveInsight Report - EIN News
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment - MSN
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MyChesCo
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today
Galera Therapeutics director Nancy Chang buys $499,978 in stock By Investing.com - Investing.com South Africa
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics director Nancy Chang buys $499,978 in stock - Investing.com
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition - TipRanks
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics, Inc. acquired Nova Pharmaceuticals, Inc. - Marketscreener.com
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
The 2024 Biotech Graveyard - Fierce Biotech
Galera stockholders reject liquidation plan - Investing.com
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MyChesCo
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire
Radiotherapy Induced Oral Mucositis Treatment Market, 2032 - Global Market Insights
Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - TradingView
Travere downsizes after a failed bid for sparsentan label expansion - Pharmaceutical Technology
Candel downsizes to focus on oncolytic virus-based cancer therapies - Clinical Trials Arena
GALERA THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) - marketscreener.com
Galera Therapeutics (NASDAQ: GRTX) up 22%last chance saloon here, really - Dhaka Tribune
Galera stock downgraded at BofA on FDA snub (NASDAQ:GRTX) - Seeking Alpha
FDA Issues CRL for Avasopasem for Severe Mucositis in Head & Neck Cancer - CancerNetwork
10 Approvals To Look Out For In Q3 2023 - insights.citeline.com
Contract Suit Alleges Drug Developer Improperly Analyzed Clinical Trial Data - law.com
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer - Yahoo 財經
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Galera Expands Commercial Leadership Team - citybiz
FDA Grants Priority Review to NDA of Avasopasem for RT-Induced Severe Oral Mucositis - Targeted Oncology
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants - Stock Titan
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky - Yahoo Finance
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight - PR Newswire
FDA Approval Sought for Avasopasem for Radiotherapy-Induced Severe Oral Mucositis in Head and Neck Cancer - OncLive
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates - Yahoo Finance
Movers & Shakers: Galera, Verily, Avid and More Tap New Execs - BioSpace
Galera's avasopasem helps reduce severe esophagitis in cancer patients receiving chemoradiotherapy in trial - Seeking Alpha
2.10%
1.57%
Capitalizzazione:
|
Volume (24 ore):